U.S. and Western Data

Demographics, parenthood, and employment impacts

Respondents living with ABC represented a wide geographic distribution, with the majority located in the United States (n = 282, 73%) and a smaller, though still notable, proportion from Western Europe (n = 35, 9%).

A vast majority identified as female (n = 380, 99%), and the mean age at diagnosis was approximately 36 years (standard deviation ± 6), reflecting the younger demographic composition of this cohort. Slightly more than half of respondents (52%) were diagnosed de novo at stage IV, while 48% reported recurrence following an earlier-stage diagnosis. Among those with recurrence, the average time between initial diagnosis and metastatic progression was four years (SD ± 3). An overwhelming 98% reported a family history of breast cancer, suggesting a potential hereditary dimension that may warrant further genomic scrutiny.

Parenting responsibilities intersected significantly with the cancer experience: nearly half (48%, n = 185) of participants had children under the age of 18 at the time of the survey. These respondents faced the dual burdens of intensive caregiving and managing a progressive, incurable—highlighting the emotional and logistical demands unique to younger patients with dependent children.

In parallel, the impact on employment was profound. Across the global sample, 64% of patients reported a shift in employment status post-diagnosis, a trend closely linked to the rigors of treatment, symptom burden, and overall health deterioration, further compounding the socio-economic vulnerabilities of this population.

The diagnostic journey: delays, dismissals, and disparities

While a substantial proportion of respondents (84%) reported feeling capable of understanding and asking questions at the time of diagnosis, a significant minority (16%) did not—an important finding given the emotionally charged and information-dense nature of the initial diagnosis. This proportion underscores a critical lapse in communication and patient engagement at a foundational stage of the ABC journey.

Delays in diagnosis emerged as a dominant theme throughout the dataset. Approximately 40% of patients globally reported delaying their initial presentation to medical care. These delays were frequently attributed to the minimization or misattribution of symptoms—particularly among younger women whose presentations were often dismissed by healthcare providers. Indeed, 22% of respondents indicated they were explicitly told they were “too young” to have breast cancer.

Other contributing factors to diagnostic delays included fear of diagnosis (13%), competing time demands (9%), absence of a known family history (11%), and being in a period of breastfeeding (8%) at the time of symptom onset. This reflects a broader pattern of provider minimization and highlights the need for systemic change in how young patients are evaluated and referred for further testing.

Symptom recognition was alarmingly low even among patients who had experienced hallmark indicators of disease. Although 72% reported the presence of a hard lump, only 46% recognized it as potentially indicative of breast cancer. Recognition was markedly lower for more atypical or less widely publicized symptoms: orange peel texture (32%), local redness or warmth (33%), and visible or enlarging veins (22%). These figures highlight persistent gaps in public awareness and health literacy, especially regarding breast cancer manifestations in younger populations.

Critically, 85% of respondents were diagnosed following the self-detection of symptoms, while only 14% were diagnosed through structured healthcare pathways such as breast health screenings (7%) or routine physician visits (7%). This pattern not only reinforces the inadequacy of existing screening guidelines for younger patients but also amplifies the need for robust symptom education and clinician vigilance.

Access to precision diagnostics revealed a mixed picture: 90% of respondents had undergone genetic testing, yet only 59% had received genomic or companion testing, with 12% unsure of whether they had received such testing at all. Notably, while 87% were offered genetic testing, only 53% were offered genomic testing. The 34-percentage-point gap between genetic testing access and genomic testing access suggests that many patients may be missing opportunities for more personalized, effective treatments. This disparity likely reflects several systemic issues: inconsistent insurance coverage for comprehensive genomic profiling, variation in oncologist practices and awareness of precision medicine options, and differences in access between community and academic cancer centers.

Treatment experiences: variation, understanding, and barriers

While most respondents had access to core treatment modalities such as surgery, chemotherapy, and radiation, availability of advanced therapeutics and supportive diagnostics varied considerably by geography. In the U.S., two-thirds of respondents reported being offered genomic testing, compared to just one-third in Western Europe, a discrepancy mirrored in reports of personalized treatment planning (U.S.: 68%; Europe: 44%).

Globally, only 46% of patients indicated that they had been offered more than one treatment option, with Western Europeans particularly unlikely to report being presented with alternatives—a trend that may reflect centralized treatment algorithms or culturally embedded clinical paternalism.

While most patients (78%) reported understanding their treatment plan, nearly one in four patients (23%) began treatment without clearly understanding its purpose or expected outcomes. This gap reveals significant inconsistencies in how informed consent and shared decision-making are practiced across patient cases.

Understanding differed markedly by treatment type: patients most frequently reported clarity around surgery (71%) and radiation (62%), followed by chemotherapy (60%) and hormone therapy (59%). Targeted therapy had the lowest rate of complete understanding, with only 54% reporting full comprehension, 38% partial understanding, and 8% not understanding at all. These findings point to the need for improved communication strategies, particularly for complex or less familiar modalities.

Barriers to accessing and sustaining quality treatment were multifaceted. Respondents identified logistical and systemic barriers including difficulty managing household and caregiving responsibilities (29%), long waiting times (21%), high treatment costs (16%), inadequate personal support networks (15%), and challenges navigating healthcare systems (22%). Additionally, stigma (14%) and lack of access to the latest therapies (11%) were cited. Open-ended responses enriched these findings, illustrating further challenges such as delays stemming from misinterpretation of dense breast tissue, age-based discrimination, geographic inaccessibility, and insufficient insurance coverage.